# Ceribell, Inc.: overview CBLL · Nasdaq · CIK 1861107 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/cbll.md) · [Financials](/companies/cbll/financials.md) · [Filings](/companies/cbll/filings.md) · [Insiders](/companies/cbll/insiders.md) Latest reported revenue: [$28.1m](/filings/0001193125-26-342574.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 10, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001193125-26-342574). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [17.2](/filings/0001193125-25-264882.md) | [18.5 d](/filings/0001193125-26-067238.md) | [20.5](/filings/0001193125-26-217008.md) | [21.2](/filings/0001193125-26-342574.md) | [22.6](/filings/0001193125-25-264882.md) | [24.8 d](/filings/0001193125-26-067238.md) | [26.5](/filings/0001193125-26-217008.md) | [28.1](/filings/0001193125-26-342574.md) | | Gross margin | % | [87.3%](/filings/0001193125-25-264882.md) | [87.6% d](/filings/0001193125-26-067238.md) | [87.9%](/filings/0001193125-26-217008.md) | [88.1%](/filings/0001193125-26-342574.md) | [88.3%](/filings/0001193125-25-264882.md) | [87.3% d](/filings/0001193125-26-067238.md) | [87.3%](/filings/0001193125-26-217008.md) | [92.3%](/filings/0001193125-26-342574.md) | | Operating margin | % | [(57.8%)](/filings/0001193125-25-264882.md) | [(69.5%) d](/filings/0001193125-26-067238.md) | [(69.3%)](/filings/0001193125-26-217008.md) | [(70.5%)](/filings/0001193125-26-342574.md) | [(64.8%)](/filings/0001193125-25-264882.md) | [(58.9%) d](/filings/0001193125-26-067238.md) | [(78.3%)](/filings/0001193125-26-217008.md) | [(71.1%)](/filings/0001193125-26-342574.md) | | Net margin | % | [(60.6%)](/filings/0001193125-25-264882.md) | [(67.9%) d](/filings/0001193125-26-067238.md) | [(62.4%)](/filings/0001193125-26-342574.md) | [(64.4%)](/filings/0001193125-26-342574.md) | [(59.6%)](/filings/0001193125-25-264882.md) | [(54.6%) d](/filings/0001193125-26-067238.md) | [(74.5%)](/filings/0001193125-26-342574.md) | [(68.6%)](/filings/0001193125-26-342574.md) | | Diluted EPS | $ per share | [(1.85)](/filings/0001193125-25-264882.md) | not reported | [(0.36)](/filings/0001193125-26-217008.md) | [(0.38)](/filings/0001193125-26-342574.md) | [(0.37)](/filings/0001193125-25-264882.md) | not reported | [(0.52)](/filings/0001193125-26-217008.md) | [(0.51)](/filings/0001193125-26-342574.md) | | Free cash flow | $m | [(9.1) d](/filings/0001193125-25-264882.md) | [(10.3) d](/filings/0001193125-26-067238.md) | [(11.6)](/filings/0001193125-26-217008.md) | [(7.6) d](/filings/0001193125-26-342574.md) | [(11.5) d](/filings/0001193125-25-264882.md) | [(11.0) d](/filings/0001193125-26-067238.md) | [(19.4)](/filings/0001193125-26-217008.md) | [(12.9) d](/filings/0001193125-26-342574.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | | Revenue | $m | [45.2](/filings/0000950170-25-026773.md) | [65.4](/filings/0001193125-26-067238.md) | [89.1](/filings/0001193125-26-067238.md) | | Gross margin | % | [84.4%](/filings/0000950170-25-026773.md) | [86.7%](/filings/0001193125-26-067238.md) | [87.9%](/filings/0001193125-26-067238.md) | | Operating margin | % | [(66.4%)](/filings/0000950170-25-026773.md) | [(60.7%)](/filings/0001193125-26-067238.md) | [(65.6%)](/filings/0001193125-26-067238.md) | | Net margin | % | [(65.1%)](/filings/0000950170-25-026773.md) | [(61.8%)](/filings/0001193125-26-067238.md) | [(60.0%)](/filings/0001193125-26-067238.md) | | Diluted EPS | $ per share | [(5.56)](/filings/0000950170-25-026773.md) | [(3.39)](/filings/0001193125-26-067238.md) | [(1.46)](/filings/0001193125-26-067238.md) | | Free cash flow | $m | [(30.1)](/filings/0000950170-25-026773.md) | [(36.4)](/filings/0001193125-26-067238.md) | [(41.6)](/filings/0001193125-26-067238.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/cbll/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [FMR LLC](/funds/315066.md) | 2026-06-30 | $110.7m | 5,691,393 | | Added +840,962 | | [TPG GP A, LLC](/funds/1903793.md) | 2026-06-30 | $73.2m | 3,761,154 | | Reduced −206,268 | | [RED TREE MANAGEMENT, LLC](/funds/2055980.md) | 2026-06-30 | $42.9m | 2,205,661 | | Unchanged | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $37.7m | 1,936,093 | | Added +122,938 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $22.0m | 1,130,346 | | Reduced −6,786 | | [KCM Capital Inc](/funds/2026745.md) | 2026-06-30 | $21.9m | 1,125,000 | | Reduced −275,000 | | [FEDERATED HERMES, INC.](/funds/1056288.md) | 2026-06-30 | $18.3m | 939,600 | | Added +136 | | [FRANKLIN RESOURCES INC](/funds/38777.md) | 2026-06-30 | $17.9m | 918,349 | | Added +108,835 | | [ADAGE CAPITAL PARTNERS GP, L.L.C.](/funds/1165408.md) | 2026-06-30 | $17.5m | 900,000 | | Added +143,249 | | [Bank of New York Mellon Corp](/funds/1390777.md) | 2026-06-30 | $17.4m | 896,488 | | Reduced −264,279 | ## Recent filings [All 301 filings](/companies/cbll/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-08-10 | 20:50 ET | [10-Q](/filings/0001193125-26-342574.md) | Quarterly report, period 2026-06-30 | 0001193125-26-342574 | | 2026-08-10 | 20:27 ET | [8-K](/filings/0001193125-26-342463.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-342463 | | 2026-07-30 | 23:00 ET | [8-K](/filings/0001193125-26-324378.md) | 5.02 Departure or appointment of officers or directors | 0001193125-26-324378 | | 2026-06-02 | 20:19 ET | [8-K](/filings/0001193125-26-253558.md) | 5.07 Shareholder vote results | 0001193125-26-253558 | | 2026-05-11 | 20:49 ET | [10-Q](/filings/0001193125-26-217008.md) | Quarterly report, period 2026-03-31 | 0001193125-26-217008 | | 2026-05-11 | 20:16 ET | [8-K](/filings/0001193125-26-216821.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-216821 | | 2026-04-20 | 16:18 ET | [DEF 14A](/filings/0001193125-26-163290.md) | Proxy statement, period 2026-06-02 | 0001193125-26-163290 | | 2026-02-24 | 21:36 ET | [10-K](/filings/0001193125-26-067238.md) | Annual report, period 2025-12-31 | 0001193125-26-067238 | | 2026-02-24 | 21:23 ET | [8-K](/filings/0001193125-26-067136.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-067136 | | 2026-01-05 | 15:53 ET | [8-K](/filings/0001193125-26-001800.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-001800 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-067238.md), filed Feb 24, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/edde521e-5a70-49a5-ade2-1638a341a35e) ## About the filer - CIK: 1861107 - Tickers: CBLL - Exchange: Nasdaq - SIC code: 3845 Electromedical & Electrotherapeutic Apparatus - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company
Emerging growth company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:49 ET. No prices; not investment advice.